Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

darovasertib (IDE196)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ideaya Biosci, Novartis

Drug class:

PKC inhibitor

Related drugs:

‹

›

GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3
PRKCH-SPTB fusion	Cutaneous Melanoma	PRKCH-SPTB fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH fusion	Cutaneous Melanoma	PRKCH fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH fusion	Colorectal Cancer	PRKCH fusion	Colorectal Cancer	IDE196 Resistant: D – Preclinical IDE196 Resistant : D	IDE196 Resistant: D – Preclinical IDE196 Resistant : D
PRKCH-SPTB fusion	Colorectal Cancer	PRKCH-SPTB fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
PRKCH-VWA2 fusion	Colorectal Cancer	PRKCH-VWA2 fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
HIF1A-PRKCH fusion	Colorectal Cancer	HIF1A-PRKCH fusion	Colorectal Cancer	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D
HIF1A-PRKCH fusion	Cutaneous Melanoma	HIF1A-PRKCH fusion	Cutaneous Melanoma	IDE196 Resistant: D – Preclinical IDE196 Resistant : D	IDE196 Resistant: D – Preclinical IDE196 Resistant : D
PRKCH-VWA2 fusion	Cutaneous Melanoma	PRKCH-VWA2 fusion	Cutaneous Melanoma	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D	IDE196 Sensitive: D – Preclinical IDE196 Sensitive : D